Bayer (FRA:BAYN) received a €90.00 ($104.65) target price from research analysts at Liberum Capital in a research report issued to clients and investors on Wednesday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the healthcare company’s stock. Liberum Capital’s price objective points to a potential upside of 19.84% from the company’s previous close.
BAYN has been the subject of several other research reports. Kepler Capital Markets set a €73.00 ($84.88) target price on Bayer and gave the stock a “neutral” rating in a research report on Thursday, January 9th. Baader Bank set a €123.00 ($143.02) target price on Bayer and gave the stock a “buy” rating in a research report on Monday. Morgan Stanley set a €86.00 ($100.00) target price on Bayer and gave the stock a “buy” rating in a research report on Monday, January 6th. Barclays set a €90.00 ($104.65) target price on Bayer and gave the stock a “buy” rating in a research report on Thursday, January 16th. Finally, DZ Bank reissued a “buy” rating on shares of Bayer in a research report on Thursday, January 16th. Eight analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Bayer has an average rating of “Buy” and an average price target of €81.61 ($94.90).
BAYN opened at €75.10 ($87.33) on Wednesday. Bayer has a one year low of €91.58 ($106.49) and a one year high of €123.82 ($143.98). The business has a 50 day simple moving average of €72.40 and a two-hundred day simple moving average of €66.63.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Recommended Story: Profit Margin
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.